fludarabine and Angiogenesis, Pathologic

fludarabine has been researched along with Angiogenesis, Pathologic in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Aymerich, M; Campo, E; Colomer, D; López-Guerra, M; López-Otín, C; Matas-Céspedes, A; Montraveta, A; Pérez-Galán, P; Roldán, J; Rosich, L; Roué, G; Villamor, N; Xargay-Torrent, S	1
Molica, S; Ribatti, D; Tucc, L; Vacca, A	1
Barr, P; Cooper, B; Creger, R; Fu, P; Hartman, P; Kane, D; Laughlin, M; Lazarus, H; Meyerson, H; Reyes, R; Stear, K; Tse, W	1

Trials

1 trial(s) available for fludarabine and Angiogenesis, Pathologic

Article	Year
Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia. Leukemia & lymphoma, 2007, Volume: 48, Issue:10 Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neovascularization, Pathologic; Thalidomide; Thrombocytopenia; Topotecan; Vascular Endothelial Growth Factor A; Vidarabine	2007

Article

Year

Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia.

Leukemia & lymphoma, 2007, Volume: 48, Issue:10

Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neovascularization, Pathologic; Thalidomide; Thrombocytopenia; Topotecan; Vascular Endothelial Growth Factor A; Vidarabine

2007

Other Studies

2 other study(ies) available for fludarabine and Angiogenesis, Pathologic

Article	Year
The γ-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells. Leukemia, 2015, Volume: 29, Issue:1 Topics: Aged; Amyloid Precursor Protein Secretases; Enzyme Inhibitors; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Neoplasm Invasiveness; Neoplasm Metastasis; Neovascularization, Pathologic; Receptor, Notch1; Tetrahydronaphthalenes; Tumor Cells, Cultured; Valine; Vidarabine	2015
Reversal of bone marrow angiogenesis in chronic lymphocytic leukemia following fludarabine therapy. Haematologica, 2005, Volume: 90, Issue:5 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bone Marrow; Chlorambucil; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Microcirculation; Middle Aged; Neoplasm, Residual; Neovascularization, Pathologic; Vidarabine	2005

Article

Year

The γ-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells.

Leukemia, 2015, Volume: 29, Issue:1

Topics: Aged; Amyloid Precursor Protein Secretases; Enzyme Inhibitors; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Neoplasm Invasiveness; Neoplasm Metastasis; Neovascularization, Pathologic; Receptor, Notch1; Tetrahydronaphthalenes; Tumor Cells, Cultured; Valine; Vidarabine

2015

Reversal of bone marrow angiogenesis in chronic lymphocytic leukemia following fludarabine therapy.

Haematologica, 2005, Volume: 90, Issue:5

Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bone Marrow; Chlorambucil; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Microcirculation; Middle Aged; Neoplasm, Residual; Neovascularization, Pathologic; Vidarabine

2005